Metastatic Lung Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Metastatic Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Metastatic lung cancer, also known as stage IV lung cancer, is an advanced form of lung cancer characterized by the spread of cancerous cells from the lungs to distant parts of the body. It typically occurs when cancer cells break away from the primary tumor in the lungs and travel through the bloodstream or lymphatic system to other organs or tissues, forming secondary tumors. The two primary types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both types can metastasize, but the most common type that spreads beyond the lungs is NSCLC.
The Metastatic Lung Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Metastatic Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Lung Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Metastatic Lung Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 55 molecules, with 47 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Metastatic Lung Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Metastatic Lung Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metastatic Lung Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ABM Therapeutics IncAccurius Therapeutics Inc
AntiCancer Inc
Arjuna Therapeutics
Arrogene Inc
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
Beijing FuKangren Bio-pharm Tech Co Ltd
Bristol-Myers Squibb Co
BrYet US Inc
Cancer Targeting Systems Inc
CiMaas BV
Compass Therapeutics Inc
Convalife
CTx Operations Inc
DeoBioSciences Inc
Enfuego Therapeutics Inc
For-Robin Inc
Genemedicine Ltd
Harry Perkins Institute of Medical Research
Hiroshima University
Hokkaido University
Huabo Biopharm (Shanghai) Co Ltd
I-Mab
Immupharma Plc
Institute of Cancer Research
Isarna Therapeutics GmbH
Kadmon Holdings Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
LeadArtis SL
MetaStat Inc
Moleculin Biotech Inc
National Cancer Institute US
Nob Hill Therapeutics Inc
Park of Active Molecules
PIN Pharma Inc
Polyplus-Transfection SA
Portage Biotech Inc
Princeton University
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Replimune Ltd
Roquefort Therapeutics Plc
SL Bigen Co Ltd
SynDevRx Inc
University of California Riverside
University of Strathclyde
Vaxil Bio Therapeutics Ltd
ViruCure Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Metastatic Lung Cancer reports